Just Out : Motley Fool " Given ACAD Met All Endpoints, New Drug Application 2nd Qt" Article.
Motley Fool By: Sean William 2/23/11
Pimavanserin, its antipsychotic drug for those with Parkinson's disease, met both its primary and secondary endpoints in late-stage trials. According to Acadia, Pimavanserin demonstrated "highly significant antipsychotic efficacy" and also helped to improve motoric tolerability. Given that it met both primary and secondary endpoints, and was well tolerated by patients, I can only imagine a new drug application is in the offing in the second quarter.